April Rule, Or April Fool? Will Final LDT Rule Be Ready On Time?

 
• By Brian Bossetta

The White House has indicated that it expects the US FDA to publish its final rule on regulating lab-developed tests by April. But first, the agency must consider thousands of comments that have poured in since the proposal was published in October.

APRIL FOOL
• Source: Shutterstock

As the Food and Drug Administration sifts through a tsunami of comments on its proposal to regulate lab-developed tests as medical devices, some are skeptical the agency can meet the White House’s expectations for finalizing the rule by April.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

South Korea Adds Digital Health Rules To Already Complicated Regulatory Landscape

 
• By Elizabeth Orr

A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.

Switzerland Investigates Private Sector Assessment of FDA-Approved Medical Devices

 
• By Amanda Maxwell

Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.

New Guidance From Canada’s HTA Agency On Submission Of AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.